MCI Onehealth to Present at Canaccord Genuity Growth globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Fernando Massalin |
For media enquiries please contact:
Nolan Reeds | nolan@mcionehealth.com | +1 (416) 440-4040 ext 158
Forward Looking Statements
This press release may contain forward‐looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation, which reflect MCI’s current expectations regarding future events. Forward-looking statements in this press release include statements with respect to the timing of the release of MCI’s financial results for the first quarter of 2021 and the timing of its earnings call to discuss those results. The words “will”, “expanding”, “growing” and other similar expressions identify forward-looking statements. Such forward-looking statements are based on various assumptions, including the time required to prepare and file MCI’s first quarter results, and are subject to numerous risks and uncertainties, many of which are beyond MCI
Article content
TORONTO, April 29, 2021 (GLOBE NEWSWIRE) MCI Onehealth Technologies Inc. (“MCI”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, announces an initial investment in Ariel Precision Medicine, Inc. (“Ariel”) in exchange for a convertible promissory note that is convertible into equity securities in Ariel upon certain events. The investment supports the growth of Ariel while establishing a foundation for a collaborative commercial partnership and future entry for MCI into the United States market. With Ariel’s focus on precision diagnosis and targeted therapeutics, this investment is anticipated to advance MCI’s precision medicine and technology roadmap by accelerating both clinical and commercial projects with pharmaceutical, medical device and life sciences companies.